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ABSTRACT

Altered metabolism can occur when the metabolic
hormones, leptin and thyroid hormone become unresponsive to

blood nutrient levels. Leptin is secreted from adipose

tissue in response to food intake, resulting in appetite

suppression and increased metabolism. Thyroid hormone (T3)
regulates genes involved in energy utilization, lipolysis,
and lipogenesis, and stimulates metabolism.

Obese mice (ob/ob) are leptin deficient and are widely

used to study the effects of leptin on metabolism. In this
study, twenty nine week old C57BL/6J ob/ob mice were
injected for seven days with vehicle, leptin, iopanoic acid
(IOP, to reduce T3 concentration) , or a combination of

leptin and IOP (n=5/group). Mice were analyzed for changes
in mass-specific oxygen consumption, respiratory quotient,

body weight, and food intake over the treatment period.
Hepatic lipid content and lipid droplet size, and adipocyte

area were determined post mortem.
Leptin decreased liver lipid content and lipid droplet
size, and increased omental adipocyte area, suggesting

leptin has the ability to reduce excess lipid storage in
the liver by shuttling lipid to adipocytes. The IOP treated

mice were not different from the vehicle treated mice with

regards to adipocyte area and liver lipid content. The
leptin/IOP treated mice had increased hepatic lipid content
and lipid droplet size, and the smallest adipocytes. This

suggests that reduced thyroid hormone is the limiting
factor regarding metabolizing and exportation of hepatic
lipids, and suggests a possible link between thyroid

hormone and leptin in regulating lipid metabolism.
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CHAPTER ONE

LITERATURE REVIEW OF ENERGY HOMEOSTASIS

Background
Obesity has become an increasingly serious problem in
the Western hemisphere and can cause serious health

problems, primarily cardiovascular disease. The cellular
mechanisms underlying the development of obesity have been

obscure, but in 1994 the discovery of the hormone leptin

changed the way obesity and diabetes research was conducted
and provided a new way to approach the study of the

metabolic syndrome (Zhang et al. 1994). Obesity may result

from improper eating, leading to an increase in fat stores,
which leads to an altered metabolism. Altered metabolism
occurs when cells that produce hormones involved in

nutrient trafficking become unresponsive to blood nutrient

levels, resulting in uncontrolled appetite and improper

storage of nutrients. It is important to study how the key
metabolic hormones, insulin, leptin, and thyroid hormone,
alter metabolic pathways and lipid and glucose trafficking
in order to find possible therapies for treatment of

obesity and its complications.
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Energy Homeostasis
Energy homeostasis is the regulation of body weight by
the brain and peripheral tissues to maintain a stable,

internal environment in the presence of a dynamic external
environment. This is dependent upon the balance between
food intake as well as anabolic and catabolic pathways, or
the building up and breaking down of molecules,

respectively. Particularly, signals from peripheral tissues
are transmitted to the brain when a change in body energy

reserves are "sensed" due to alterations in energy

expenditure, nutrient partitioning, and energy intake.
Maintenance of energy homeostasis is a complex process
that is mediated by multiple endocrine and neurocrine

feedback loops to and from the central nervous system (CNS)
and involves cross-talk among many tissues, including the

brain, liver, skeletal muscle, stomach, pancreas, and

adipose tissue. The sympathetic nervous system (SNS) of the
CNS regulates whole body metabolism by its actions on

neurons of the hypothalamus. These neurons secrete

neurohormones (releasing hormones) that trigger the
secretion of hormones from the anterior pituitary gland. In

turn, the pituitary gland links the nervous and endocrine

systems. The anterior pituitary hormones bind to specific
2

cellular receptors, eliciting their respective responses,

which can then feedback to the SNS to turn down their
secretion.

The SNS is important in regulating appetite. Feeding
is regulated by signals from the arcuate nucleus located
within the hypothalamus (Elmquist et al. 1998b).

Neuropeptide Y (NPY) and agouti-related peptide (AgRP)
stimulate appetite while proopiomelanocortin (POMC) and
melanocortin stimulating hormone (oc-MSH) induce a decrease
in appetite (figure 1). NPY is also known to inhibit

thermogenesis (Billington et al. 1991; Dryden and Williams
1996). Decreased thermogenesis reduces oxygen consumption,
allowing nutrients (glucose and lipids) to be stored
instead of being utilized to support oxygen consumption. A
rise in stored nutrients reduces appetite stimulation so
that overeating does not occur.

Neurons of the hypothalamus are stimulated by the
hormones ghrelin, insulin, and leptin, which in turn are
regulated by circulating glucose and free fatty acid levels

and intracellular glycogen and triacylglycerol (TG) stores

(Houseknecht 1998). While ghrelin stimulates appetite
through AgRP and NPY, insulin and leptin cause appetite

inhibition through inhibition of the same neurons and
3

Figure 1. Hormonal Control of Feeding Regulation.
Feeding regulation is controlled by hormones
released from the stomach, pancreas, and adipose
tissue. When nutrients are available, insulin and
leptin are secreted from the pancreas and
adipocytes, respectively, to inhibit AgRP and NPY
while simultaneously stimulating POMC and aMSH. This
inhibition and stimulation leads to an inhibition of
feeding on the PVN. When nutrients are absent,
ghrelin is released from the stomach/duodenum and
stimulates AgRP and NPY, which leads to a
stimulation of feeding on the PVN. AgRP= agoutirelated peptide; NPY= Neuropeptide Y; POMC=
proopiomelanocortin; aMSH= melanocortin stimulating
hormone; PVN= paraventricular nucleus

stimulation of POMC and a-MSH (figure 1).

(Due to the focus

of this thesis, ghrelin will not be discussed. For further
information see review by Lazarczyk et al. 2003.) Insulin
is secreted from pancreatic p cells when plasma glucose

levels rise after a meal and through its actions on the
4

hypothalamus, it stimulates glucose and free fatty acid

uptake into peripheral tissues. Glucose uptake in skeletal

muscle and adipose tissue is directly dependent on insulin.
However, in the liver, insulin indirectly facilitates

diffusion of glucose into hepatocytes, but some glucose can
still diffuse into hepatocytes even in the absence of

insulin. When glucose enters hepatocytes, it can

immediately enter glycolysis, increasing the production of
cellular energy, or be converted to its storage form,

glycogen. If insulin is oversecreted due to chronic

elevated plasma glucose (e.g. from overeating), its signal

on cells will be ignored, referred to as accommodation or
insulin resistance. Insulin resistance will decrease

glucose uptake and lead to hyperglycemia (Houseknecht et
al. 1998a).

While insulin elicits its responses over the short

term (hours), leptin can elicit the same responses over the
longer term (days). Leptin is a hormone of the cytokine

family and is secreted by adipose cells in response to
energy intake (Tartaglia et al. 1995). In addition to

insulin-like effects, leptin can also control feeding
behavior (Houseknecht et al. 1998b).

For instance, when

adipocytes increase in size due to a post-prandial (after

5

meal) increase in stored nutrients, leptin is secreted from

adipocytes to inhibit appetite. Lack of appetite

inhibition, i.e. low leptin levels, can lead to overeating.
There is an importance in understanding the changes in

glucose and lipid metabolism in response to nutritional

status in obese individuals, who may be leptin deficient

(Houseknecht et al. 1998b).
Leptin gene expression is regulated by the size of

adipocytes as well as insulin and glucocorticoids (Caro et
al. 1996). There is a positive correlation between adipose

tissue mass and fat cell size to the quantity of leptin
secreted (Houseknecht et al. 1998a; Caro et al. 1996).

Adipose cells sense excess fat storage and stimulate the

release of leptin, which then leads to an increase in total
body energy expenditure, decreased food intake, and
normalization of body weight in obese mice within 2 weeks

or less (Halaas et al. 1995; Maffei et al. 1995). Leptin

acts either directly, binding to receptors on its target
cells (e.g. liver), or indirectly by binding to leptin

receptors in the hypothalamus because leptin is able to

penetrate the blood-brain barrier. Leptin that targets the

hypothalamus then stimulates the release of neurohormones,
such as thyroid stimulating hormone and growth hormone

6

(Houseknecht et al. 1998b), from the pituitary to induce
their respective cellular responses (Elmquist et al. 1998b;

Houseknecht et al. 1998b; Fehn et al. 1999). Pelleymounter
et al.

(1995) showed that leptin administration to leptin

deficient obese mice (ob/obr refer to section "the ob/ob

mouse model", p. 23) stimulated an increase in basal

metabolic rate and thermogenesis, leading to a reduction in
body weight. The administration of leptin to ob/ob mice
decreases food intake and restores neuroendocrine functions
that are lost as a result of leptin deficiency. These

include infertility derived from decreased hypothalamic

leutinizing hormone secretion in ob/ob mice, among other
reproductive abnormalities (Halaas et al. 1995;

Pelleymounter et al. 1995; Campfield et al. 1995; Chehab et
al. 1996).

Furthermore, Fehn et al.

(1999) showed that

leptin administration also increased thyroid hormone
concentrations in ob/ob mice due to enhanced thyroid

follicular cell activity leading to enlarged colloids. Reno
and Fehn (2007) also showed that SNS-ablated ob/ob mice and

hyperthyroid ob/ob mice were rescued from hepatic steatosis

(fatty liver) with administration of leptin. This result
shows that leptin can elicit physiological responses

independently of the SNS and in the presence of excess
7

thyroid hormone, supporting the importance of leptin in
maintaining energy homeostasis. However, the extent of
these responses has only been studied at a histological

level and needs to be examined further by molecular
analyses. Additionally, when the SNS is activated by

leptin, lipolysis in white adipose tissue is stimulated

(Siegrist-Kaiser et al. 1997; Fruhbeck et al. 1997),

releasing free fatty acids for use in metabolism.
The pathologies 'associated with obesity and diabetes,

among others, are often linked with either a complete
absence of leptin or the brain's inability to respond to

leptin (i.e. leptin resistance) because without leptin's
actions, there is improper storage and release of glucose
and fatty acids, primarily in adipocytes and hepatocytes

(Halaas et al. 1995; Pelleymounter et al. 1995; Campfield

et al. 1995; Chehab et al. 1996).
Even though leptin can affect energy metabolism

through the hypothalamus (i.e. CNS) and/or through
receptors located directly on peripheral tissues (Elmquist
et al. 1998; Houseknecht et al. 1998b; Fehn et al. 1999;
Fei et al. 1997; Elmquist et al. 1998a; Mercer et al. 1996;

Schwartz et al. 1996), research has primarily focused on
its CNS effects (Tartaglia et al. 1995; Caro et al. 1996;
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Halaas et al. 1995; Pelleymounter et al. 1995). Recently,
this focus has shifted to trying to understand the

mechanisms of direct leptin stimulation of peripheral

target cells. The cellular responses to leptin are

dependent on the concentrations of circulating glucose,

free fatty acids, and other hormones such as insulin
(Houseknecht et al. 1998a; Stephens and Caro 1998). The
liver is one of the main regulators of macronutrient
metabolism, controlling serum free fatty acid and glucose

levels in response to serum leptin concentrations. Serum
glucose levels affect the activity of key enzymes involved

in metabolic processes, such as glycolysis and (5-oxidation.

After sufficient quantities of glucose are taken up into
tissues (primarily liver) to meet energy requirements,
glucose is converted into its storage form, glycogen, in
order to prevent excess secretion of glucose back into the

blood. During the post-prandial period, a rise in serum

glucose levels causes pancreatic B cells to secrete insulin

(figure 2), which activates glycogen synthetase and leads

to an increase in hepatic glycogen storage. In a fasting
state, pancreatic a cells respond to the serum glucose
deficiency and secrete glucagon, which together with
epinephrine activates phosphorylase in the liver to convert

9

Glucose Regulation By Pancreatic Cells

R. Felm

Figure 2. Glucose Regulation by Pancreatic a and 0
Cells. Increases in plasma glucose are sensed by
pancreatic 0 cells, which secrete insulin, signaling the
liver to store glucose. High levels of plasma glucose
also inhibit glucagon secretion from pancreatic ot cells.
Plasma glucose deficiency is sensed by pancreatic, ex
cells, leading to glucagon secretion and the release of
glucose from the liver. Pancreatic ot cells also stimulate
insulin secretion from pancreatic 0 cells, preventing
hyperglycemia due to hepatic glucose release.

glycogen into glucose. This glucose is released from the

liver into the blood to be used for cellular energy by
peripheral tissues via glycolysis. Since glycolysis
produces acetyl-CoA, which is required to produce fatty

acids, the concentration of glucose or glycogen present in
the liver can indirectly control the rate of fatty acid
formation, which can affect the amount of fatty acid stored

as TG. For example, if hepatic glucose concentrations

increase to support an increase in glycolysis, then more
10

fatty acids can be built, causing the excess fatty acids to

be stored as TG (Gibbons et al. 2000).

In addition to stimulating the conversion of glycogen
to glucose, glucagon can also stimulate lipolysis in

adipose tissues, which decreases the size of adipocytes and
provides free fatty acids to potentially be utilized in

hepatic glucogenesis. Furthermore, glucagon stimulates the

activity of enzymes that lead to the [3-oxidation of fatty

acids. Abnormalities associated with increased serum
glucagon can cause' the release of excess glucose and fatty

acids into the blood, which then leads to altered insulin
sensitivity. If insulin sensitivity is decreased, then the
storage and release of glucose will be decreased and that
of fatty acids increased. This reduced glucose uptake into

adipose tissue and skeletal muscle due to insulin
resistance can lead to hyperglycemia, hyperlipidemia,

and/or excess TG storage in the liver. The overproduction

of both hepatic glucose and fatty acids can occur as a
result of chronic overeating.

This leads to a mistaken

sensation of low plasma glucose and fatty acids by the
pancreas due to altered glucose and lipid trafficking.

Overproduction of glucose and fatty acids leads to
hypersecretion of these molecules into the blood. This
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causes a rise in serum glucose and free fatty acid levels
and stimulates the release of more insulin from pancreatic

3 cells, which will exacerbate peripheral insulin
resistance (McGarry 1992), a key factor in the development

of obesity and type II diabetes. Once insulin resistance

occurs, there is a continual sensation of excess
macronutrients in the blood, and this condition will cause
excessive storage of the glucose and fatty acids, not only
in adipocytes, but in hepatocytes as well. Therefore, the

control of glucose production and release is a key factor

in regulating overall lipid metabolism.
Lipids

Obesity and diabetes are associated with dysregulation
of hepatic lipid synthesis. Acetyl-CoA carboxylase (ACC)

and fatty acid synthase (FAS) are hepatic lipogenic enzymes
whose gene transcription is regulated by cellular nutrient

levels (Towle et al. 1997). Fatty acids are synthesized
when cellular energy is .in demand and are either utilized

immediately or combined with glycerol to form TG to be
stored as neutral lipids. Neutral lipids, including

triacylglycerols (TG), steryl esters (SE), and wax esters
(WE), are lipids which are unable to penetrate

phospholipids bilayers (Athenstaedt and Daum 2006) .
12

Sterols, free fatty acids, and diacylglycerols (DAG) are

stored intracellularly after conversion to TGs and SEs. TGs
are the major form of lipid storage within tissues, and the

fatty acids stored as TG may be oxidized by [3-oxidation to

produce cellular energy. Therefore, regulation of the
release of fatty acids from their neutral lipid storage

form may be key in regulating metabolic expenditure.

Neutral lipids are stored in intracellular
compartments called lipid droplets (LD). The lipid droplet

consists of a phospholipid monolayer, with just a few
embedded proteins that control the extraction and

hydrolysis of lipids from LDs, and a hydrophobic core
containing the neutral lipids (Athenstaedt and Daum 2006).
Lipases and hydrolases regulate the release of neutral

lipids from the cores of LDs. These neutral lipids can then
be broken down to fatty acids that can be utilized by the
cell. The free fatty acids and DAG are oxidized primarily

for energy.
The exact mechanisms of how LDs form are still under

investigation. Van Meer (2001), Ostemeyer et al.
and Murphy et al.

(2001)',

(1999) propose that as neutral lipids are

being synthesized between the two leaflets of the

endoplasmic reticulum (ER), they accumulate due to their
13

inability to pass through the ER membrane. Once the neutral

lipids reach a certain size, they bud off one leaflet of
the ER and enter the cytosol as a lipid droplet. Once lipid

droplets are formed, they can increase in size by de novo

synthesis of neutral lipid using enzymes embedded in the
phospholipid monolayer and/or within the core of the LD

(Athenstaedt and Daum 2006). The core contains the
necessary components necessary to make the precursors that

form TG. Pathologies associated with obesity and diabetes
arise in part because of problems accessing neutral lipids

in the LDs to extract the fatty acids. This problem results
in the accumulation of excess lipids and larger LDs within
the liver and adipose tissue (Greenberg et al. 2006).

Adipose Tissue and Triacylglycerol Hydrolysis
Adipose tissue is not only a major storage depot for

excess fat, but more recently it has been found to be an

endocrine organ involved in the regulation of whole-body

metabolism (Mohamed-Ali et al. 1998). While leptin is
secreted from adipose tissue, other hormones such as

thyroid hormone may stimulate adipose tissue to further

regulate metabolism. Leptin and thyroid hormone regulate
the activity of adipose lipolytic enzymes and thus .control

the hydrolysis of TG within adipocytes. Hormone sensitive
14

lipase (HSL) is the best-studied adipose lipase and works
to induce lipolysis via a cyclic-AMP (cAMP)-meditated
phosphorylation cascade that translocates HSL to the

surface of LDs where it can then access and hydrolize the
newly released TG into glycerol and fatty acids. In
addition to HSL, other lipases may be activated by other

cell signals that regulate the same process. For instance,
deletion of the murine HSL gene only decreased half of the

TG lipase activity in adipocytes, suggesting that at least
one other enzyme also facilitates this process (Wang et al.
2001; Osuga et al. 2000). Triacylglycerol hydrolase (TGH)

is also found in adipose tissue (Dolinsky et al. 2001). W.
Gao and R. Lehner showed that reducing murine TGH

expression reduced adipocyte free fatty acid release and
caused a 40% decrease in plasma free fatty acids

(Athenstaedt and Daum 2006). More recently, adipose
triglyceride lipase (ATGL) was discovered by Zimmerman et

al.

(2004), and they demonstrated that ATGL is responsible

for 70% of TG lipase activity in adipose tissue, an

apparent conflict with previous reports on HSL and TGH
activity. This result suggests that the activity of HSL and
TGH may have been overestimated and that ATGL might be just

as important for lipolysis. More work is needed to examine
15

the possibility that the activity of any of the lipases is

affected by the absence or presence of the other ones.
The hydrolysis of TG occurs in response to a signal

released from the SNS that fatty acids are needed for

metabolism. These fatty acids are secreted into the
bloodstream for circulation to their target tissues,

primarily skeletal muscle and liver. If they are not needed
in these tissues or cannot be taken up due to insulin

insensitivity, they may remain in circulation for longer
periods of time. The misregulation of the release and

hydrolysis of TG is a critical factor in the development of
insulin resistance, hyperinsulinemia, hyperglycemia, and

dyslipidemia because glucose uptake into muscle and liver
is also altered when there is a chronic increase in

circulating free fatty acids (Boden and Shulman 2002; Boden
2003). Thus, the genes and proteins that control the

activity of HSL, TGH, and ATGL are possible links to the
observed defects in the obese syndrome that leads to

insulin resistance.

Thyroid Hormone
The thyroid gland is an important organ that is

involved in various physiological processes. A negative
feedback loop that involves the hypothalamus, pituitary,

16

and thyroid gland controls the synthesis and secretion of

thyroid hormones (Shupnik et al. 1989). Thyroid hormones
are derived from the amino acid tyrosine. The two main

types of thyroid hormones are 3,5,3',5'-tetraiodo-L-

thyronine (T4) and 3,5,3'-triido-L-thyronine (T3) , which
differ by the number of iodide ions they contain. Iodide is
taken up by the follicular cells of the thyroid gland via a

Na+-I” co-transport system driven by the plasma membrane Na+

gradient and becomes oxidized to an active form. This
reactive iodide reacts with specific tyrosine residues

within thyroglobulin (Tg, protein produced by thyroid

gland) via oxidative coupling to form either 3monoiodotyrosine (MIT) or 3, 5-diiodotyrosine (DIT). If two
DIT moieties are joined together, then T4 is produced. If

one MIT and one DIT moiety are joined, then T3 is produced.
The signal to produce thyroid hormones occurs when the

pituitary gland releases thyroid stimulating hormone (TSH),
which stimulates intracellular cAMP production in the

follicular cells of the thyroid gland, leading to the
production of T4 and T3. Tg contains MIT, DIT, T3, and T4 and
is stored as a colloid droplet within the follicular lumen
for immediate release when needed. To release T4 and T3, Tg
undergoes endocytosis from the lumen at the apical surface

17

of the follicular cell and is digested inside the cell to

release the hormones, which then diffuse into the blood
vessels for circulation to their target tissues (Taurog
1996).

Total serum T4 is 40-fold higher than total serum T3;

however, T4 is not as widely used by target tissues as T3,
but both T4 and T3 have been shown to produce physiological
responses. Most of the serum T3 and T4 are bound to
thyroxine binding globulin, albumin, or thyroid binding

prealbumin when in an inactive form. Thyroid hormones must

be released from the protein carriers to enter target cells
to elicit biological responses. T3 is involved in numerous

physiological processes and is in higher abundance in the

free form than T4 (Yen 2001) . However, even though free T3
is more abundant than free T4, most of the T3 effects are
exerted when T4 is converted to T3 locally at the tissues

(Yen 2001) . At the liver and kidney, T4 is converted to T3
by type I deiodinase, and this accounts for most of the T4

turnover observed in circulation (Braverman et al. 1970;
Kohrle 2000). Additionally, T4 is converted to T3

intracellularly by type II deiodinase in the brain,

pituitary, and brown adipose tissue.

18

Both thyroid hormones activate transcription of
specific genes by binding to a member of the thyroid
receptor (TR) family located in the nucleus of cells of
various organs. When T3 is bound to TR, gene transcription
is activated through thyroid response elements (TRE), which
are sometimes pre-bound to TRs, located on the promoter
regions of target genes. When T3 is not bound to TRs, there

is repression of gene transcription (Zhang and Lazar 2000).

Thyroid Hormone and Adipose Tissue

Adipocyte differentiation has been shown to be induced
by T3. Grimaldi et al.

(1982) demonstrated that

preadipocytes from young rats, as well as cells from
preadipocyte cell lines, were induced to become white

adipose tissue when treated with T3, as shown through

stimulated intracellular lipid accumulation, transcription
of key lipogenic enzymes, and adipocyte cell proliferation.

The lipogenic enzymes that are induced include ATP-citrate
lyase, malic enzyme, and fatty acid synthase, all of which
can lead to the synthesis of fatty acids (Blennemann et al.

1995; Gharbi-Chihi et al. 1991).

Thyroid hormones indirectly regulate lipolysis in
adipocytes by enhancing the binding of catecholamines to 0-

adrenergic receptors on adipocytes; thyroid hormones
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increase p-adrenergic receptor density and decrease

phosphodiesterase activity (Engfeldt et al. 1982;
Wahrenberg et al. 1986). p-adrenergic signaling activates
adenylate cyclase and mediates a signal transduction

cascade via the second messenger cAMP, leading to the

activation of lipases that catalyze the breakdown of
triacylglycerol (via HSL) into fatty acids and glycerol.

Therefore, lipid metabolism can be altered depending upon
thyroid status.
The quantity of circulating thyroid hormones may be

altered due to defects in the feedback loop that controls

thyroid hormone secretion. Hyperthyroidism and
hypothyroidism occur when there is over secretion and under

secretion of thyroid hormones from the thyroid gland,

respectively. During a state of hyperthyroidism,
hyperplasia (increase in cell number) and an increase in

lipolysis occurs in adipocytes (Levacher et al. 1984).

Hypothyroidism, on the other hand, results in hypertrophy
(increase in cell size) and decreased lipolysis in

adipocytes, resulting in less available free fatty acids
for metabolic use. Furthermore, hypothyroidism is

associated with low metabolic rate, low body temperature,
slow heart rate, and weight gain (Hadley 2000). Therefore,
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during hypothyroidism, adipocytes are expected to increase

in cell size when compared to a euthyroid state (normal
thyroid function) because the cells are saving energy due
to the effects of low T3.
Thyroid hormones regulate genes involved in energy

utilization, lipolysis, and lipogenesis. However, these
processes do not all occur in the same time frame. In a

study of chronic T3 injections in adult rats (Oppenheimer et
al. 1991), total oxygen consumption, which is a measurement

of metabolic rate, reached its peak in only 4 days of
treatment, and by the sixth day, the amount of total body
fat storage dropped by half. However, caloric intake did

not reach its peak until day 8, after continually

increasing during the previous treatment days. The animals
probably still lost body fat despite increased caloric

intake because metabolic rates were increased as well, and

the calories were needed to maintain energy levels that
were being depleted due to increased lipolysis.

Furthermore, transcription of genes needed for
thermogenesis, lipolysis, and lipogenesis were upregulated

by thyroid hormone before they were even needed. This
suggests that thyroid hormone-stimulated lipolysis is not
directly linked to thyroid hormone-stimulated energy
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utilization because genes needed for lipolysis are
upregulated as a default mechanism, and this occurs before

energy is required.
Thyroid Hormone and Liver
Thyroid hormones can also have multiple effects on
the liver. For instance, malic enzyme is a lipogenic enzyme

found in the liver, as well as other tissues. In a study by
Strait et al.

(1989), the transcription of hepatic malic

enzyme showed biphasic regulation, as expression increased
at 4 hours and again at 24 hours in response to T3

treatment. This suggests that while T3 has initial direct
effects, secondary effects caused by genes initially

upregulated by T3 also elicit the same type of response as
T3 on its target tissues. The specific effects of T3 on its

target tissues can be dependent upon carbohydrate intake,
insulin, and cAMP (Oppenheimer et al. 1987, 1991). Because

of these variables, there needs to be consistency in

experimental design, using either fasting or non-fasting
animals, because the presence or absence of food can alter
the activity of T3. For instance, in fasted animals, T3 has

only minimal effects on the induction of malic enzyme,
whereas animals fed a high carbohydrate diet show the
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highest levels of T3-stimulated. malic enzyme lipogenesis
(Oppenheimer et al. 1987, 1991).
Thyroid hormone regulates the expression of about 8%

of hepatic genes in vivo (Oppenheimer et al. 1987). Feng et
al.

(2000) used a cDNA microarray to identify the hepatic

genes that are regulated by thyroid hormone. In hypothyroid
mice treated with T3, microarray analysis revealed that 14

genes were up-regulated and 41 were down-regulated. These
included genes involved in various cellular processes,
including increasing glycogenolysis, gluconeogenesis,

lipogenesis, cAMP activity, [32-Adrenergic receptor
activity, proliferation, and apoptosis. It also included

genes that decreased insulin action, immunogenecity, and

protein glycosylation.
The ob/ob Mouse Model

With failed attempts to treat obese human patients

with leptin injections (Houseknecht et al. 1998a), there
has been an increasing need to understand the mechanisms
involved in lipid trafficking in order to determine

appropriate routes for therapy. Since leptin reduces
appetite and lowers fat mass in mice, it is inconclusive as

to why treatment with leptin does not work as a therapeutic
agent in humans. Abnormalities in other hormone
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concentrations that occur in obesity may hinder the action

of leptin. Leptin may possibly interact with these other

hormones to affect lipid trafficking, making the

determination of its actions alone more difficult. There
are many interacting physiological processes that occur at

any given time in the human body. Certain available animal

models may be useful in isolating certain metabolic
pathways and determining the mode of action of a single

hormone.
There are two well-known mouse models used to study

obesity and diabetes. They are the obese (ob/obr described

below) and diabetic (db/db) mice. The ob/ob mouse is leptin
deficient, but this deficiency can be rescued by injection

of leptin because leptin receptors, particularly in the
brain, are still responsive to leptin (Zhang et al. 1994).
The leptin receptors of db/db mice are nonfunctional, thus

the injection of leptin has no effect, i.e. the mice are
leptin resistant, which seems to be the case for most
humans (Ghilardi et al. 1996). Therefore, in order for the

effects of exogenous leptin on obesity to be observed, the
ob/ob mouse model needs to be used.

The mouse ob gene codes for the protein leptin. This

protein has an amino acid sequence 84% identical to that

24

found in humans (Zhang et al. 1994). The C57BL/6J ob/ob

mouse strain was first isolated by Ingalls et al.
and was later characterized by Zhang et al.

(1950)

(1994). They

found ob/ob mice express a twenty-fold increase in abnormal

ob mRNA that contain a single base substitution resulting

in a nonsense mutation. This substitution results in a
truncated leptin protein, leading to leptin protein
deficiency. The lack of leptin leads to morbid obesity,
hyperphagia, hypothermia, extreme insulin resistance,

infertility, and many other endocrine abnormalities
(Ingalls et al. 1950). The lack of an appetite inhibition
signal associated with chronic leptin deficiency can cause
the brain to perceive a starvation status even though there
are adequate circulating and stored carbohydrates and

lipids. Thus, the brain continuously stimulates appetite
and food intake, which leads to obesity (Elmquist et al.
1998b). The ob/ob mouse model is useful in investigating

how defects in lipid metabolism (due to reduced
concentrations of circulating leptin levels) lead to

serious conditions such as insulin resistance.
The roles of thyroid hormone in regulating

physiological pathways involved in metabolism, including
lipolysis, and leptin's role in maintaining the balance
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between circulating nutrient levels and the quantity stored

in various tissues, suggest these two hormones may interact
to affect lipid storage. However, it is not known if the

actions of leptin are dependent on the presence of thyroid
hormones. T3 concentrations can be lowered by the drug
iopanoic acid (IOP), which blocks the activity of type I

deiodinase, allowing the possibility to study leptin's
effects in the presence of decreased T3 levels.

Previous Work in Dr. Richard Fehn's Lab
The interactions of thyroid hormone and leptin have

been studied in Dr. Fehn's lab using both the ob/ob and

db/db mouse models to evaluate histological and molecular
data from various tissues. In a study by Brian Underhill
(2000), C57BL/6J ob/ob mice were treated for nine days with
saline vehicle, leptin, IOP, or leptin/IOP. He monitored

daily food consumption, body weight, body heat production
(measured by radiant body temperature), oxygen consumption,
respiratory quotient (RQ), and circulating T3 and T4 levels.

Results revealed that leptin and leptin/IOP treatments

caused a reduction in food consumption, while IOP treatment
showed no change. The decrease in body weight was lowest in

leptin/IOP treated mice, with leptin treatment still
causing weight loss when compared to vehicle treated mice,
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and IOP treated mice showing no change. Body heat

production was increased with leptin/IOP treatment as
compared to vehicle treatment, but mice treated with leptin

and IOP alone showed body heat production equal to that of

vehicle treated mice. Oxygen consumption rates (V02) for
leptin and leptin/IOP treated mice were the same as the

vehicle treatment. However, IOP treated mice had a lower V02

compared to the vehicle treated mice. This suggests that

leptin prevented the reduction in oxygen consumption
observed in the IOP treated mice. Furthermore, mice in all

treatments expressed RQ values representative of lipid
metabolism. Finally, T3 levels were significantly elevated
in ob/ob vehicle treated mice compared to ob/+ vehicle
treated mice, but the remaining three treatment groups in

ob/ob mice showed no difference among one another. Taken
together, these results show that reduced body weight in

leptin and leptin/IOP treated mice may be due ultimately to
decreased food consumption observed in these groups. IOP
treated mice may weigh equal to that of vehicle treated

mice because of the similar food consumption between the
two groups.
The observation that all of these mice may have been

primarily utilizing lipid to fuel metabolism may have been
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erroneous. Underhill's results were in contrast with a
later study by Reno and Fehn (2007) that found that vehicle
and IOP treated ob/ob mice had an RQ representative of

carbohydrate metabolism, while leptin treated mice had an

RQ representative of lipid metabolism. It was also
suggested by Reno and Fehn (2007) that the lipid metabolism
by any animal with leptin treatment may have been necessary

to support their increased production of body heat, which
is indicative of higher energy expenditure through

thermogenesis. On the other hand, increased thermogenesis
could also have been a result of increased lipid
metabolism.

During periods of increased energy expenditure, lipid
is the preferred metabolic substrate since lipid is stored
and readily available for use. All of the animals in both

studies started out obese, and, therefore, had abundant
lipid available for use, possibly supporting the notion

that all animals used lipid metabolism, but Underhill's

results do not follow the pattern that was seen in the
later study (Reno and Fehn 2007). For instance, Reno and

Fehn (2007) saw an increase in lipid metabolism and

suggested this could support an increase in body heat
production observed during leptin treatment. Also, the
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radiant body temperatures in Underhill's study showed that
leptin/IOP treatment increased body heat production, while
the other three treatments showed no change. Therefore, his

results demonstrated that if body heat production is one
factor that can alter which substrate is used in
metabolism, then the vehicle, leptin, and IOP treated mice

should have been using carbohydrates as a metabolic

substrate if there was no increase in energy as heat.

However, with the exception of IOP treated mice, the oxygen

consumption rates were relatively constant among the
treatment groups. Taken together, the results of both

studies reveal the importance of not one, but many factors
that underlie whether carbohydrate or lipid metabolism is

preferred. Moreover, mice may switch between carbohydrate
and lipid use in a daily cycle depending on whether they
are active or sleeping (unpublished data from Dr. Fehn's

lab) .
Another interesting contradiction was found between
previous studies reported in the literature and research in

Dr. Fehn's lab in regards to the effects of leptin

treatment. Pelleymounter et al.

(1995) state that ob/ob

mice of the C57BL/6J strain given leptin increase oxygen
consumption, while Dr. Fehn's lab (Reno and Fehn 2007;
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Underhill 2000) found no increase in leptin treated mice

compared to vehicle treated mice. Pelleymounter et al.'s
study was done on 5-week old mice over a 28 day injection

period, while the Fehn studies were done on 10-12-week old

mice over a 9 day injection period. It may be inferred that
a longer treatment period with leptin may have additional

affects, but Fehn's lab showed that after nine days of
treatment, all parameters measured in the mice reach a peak
and do not go any further. Age effects may also account for

the differences observed between the studies. For instance,

the onset of obesity in mice occurs around 5 weeks of age
and 10-12-week old mice are considered to be reproducti.vely

mature. My current study will help clarify whether or not
leptin injection stimulates significant increases in

metabolism and what effects an increased metabolism may

have on other measurable parameters such as metabolic
substrate utilization.
Due to the importance of these factors in evaluating

the end point analyses of hepatic lipids and adipocytes,
all of the afore mentioned metabolic parameters need to be

assessed again in my project. I expect the results in my
experiments to be a mix of those which found in literature
(Pelleymounter et al. 1995) and those found in the Fehn lab
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studies (Reno and Fehn 2007; Underhill 2000)

(table 1). My

study on hepatic lipid content and adipocyte area

(described below) will provide additional data on the
relationship between leptin and thyroid hormone in lipid
metabolism.

Preliminary Work and Hypotheses
Previous work has been done on C57BL/6J ob/ob mice

where these mice were treated for nine days with vehicle,

leptin, T3, IOP, 6-hydroxydopanine (6OHDA), leptin/ T3,
Leptin/6OHDA, T3/6OHDA, and T3/IOP (Reno and Fehn 2007).

Analysis of hepatic lipid content and lipid droplet size by

transmission electron microscopy (TEM) and light microscopy
revealed that treatment groups lacking leptin contained

more hepatic lipid droplets and larger lipid droplets,
suggesting lipid storage. In animals treated with

leptin/6OHDA and leptin/T3, hepatic lipid droplet size and

content were significantly decreased.

(Content was assessed

by cross-sectional area of hepatocytes.) This suggested

that leptin is very important in facilitating the breakdown
and export of stored and newly synthesized lipids because

it is able to produce its responses even under adverse

conditions. These were adverse conditions because

sympathetic neurons are important in energy homeostasis and
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Table 1. Expected Results of Parameters to be Tested.

Vehicle

Leptin

IOP

Leptin/IOP

—

T

I

—

—

J,

—

RQ

CHO

Lipid

CHO

Lipid

Food
consumption

—

X

—

4

Oxygen
consumption
rate
Body weight

IOP treated mice should have the lowest oxygen consumption
rate while leptin treated mice should have the highest. The
mice in the remaining two treatment groups should show
rates of equal value. Body weight should be reduced in
leptin and leptin/IOP treated mice, while IOP treated mice
should have body weight equal to that of vehicle treated
mice. RQ values should reveal that carbohydrates are being
utilized as a metabolic substrate in the vehicle and IOP
treated mice, but mice from the other two treatment groups
that receive leptin should show RQ values representative of
lipid metabolism. Food consumption should be reduced in
leptin and leptin/IOP treated mice, while IOP treated mice
should eat about the same amount as vehicle treated mice.
--- = no change; j, = decreased values when compared to
vehicle; CHO= carbohydrate

hyperthyroidism can lead to further metabolic

complications. Surprising results were obtained when

evaluating omental and subcutaneous adipocyte volumes:
leptin treated mice (alone and combined treatments) had the
largest adipocyte areas compared to all of the other

treatment groups. This was interesting given that leptin
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treatment reduces body weight. It was therefore assumed
that adipocytes would be smaller than adipocytes from an
obese mouse given vehicle treatment. One explanation for

the observed results is that the liver was exporting a vast

amount of stored lipids and sending them to adipose tissue
because storing lipids in adipocytes is a more efficient

way to store excess lipid. This idea is supported by the
decreased liver lipid content, decreased liver weight, and
stable glycogen levels in the liver. The stable glycogen

levels suggest that liver weight was lost not due to an
increase in metabolism but due to the export of lipids,

which then moved to adipocytes. This seems logical because
storage of excess lipid in the liver leads to serious
problems, such as liver failure and hepatic steatosis

(displacement of the cytoplasm and organelles due to excess
lipid accumulation), and adipose tissue is meant to store

lipid. In this study, total oxygen consumption did not

increase with leptin treatment, suggesting less lipid
disposal from adipocytes for metabolism.

Another interesting observation was that IOP treatment
alone caused massive hepatic steatosis. Analysis of

hepatocytes under TEM showed apoptosis likely due to

enlarged lipids distorting organelles, including the
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nucleus. Interestingly, when IOP treatment was combined
with T3, large hepatic lipid droplets were still prevalent
whereas mice treated with T3 alone had numerous small lipid
droplets. Therefore, the low T3 concentration in IOP treated

mice may not be the only underlying factor as to why
hepatic lipids are so large since T3 replacement in a T3/IOP
combined treatment still exhibited large lipid droplets.

One question that arose was if leptin can cause a
reduction in hepatic lipid droplet content and size in

animals that have SNS neuron ablation (Leptin/6OHDA) and in
animals with excess lipid synthesis (leptin/T3) , then leptin
should be able- to breakdown large lipid droplets and export

them even during the massive hepatic steatosis observed in
IOP treated animals. Thus, a combined treatment of

leptin/IOP could reveal whether or not low T3 concentration

has an effect on hepatic lipid transport even in the

presence of leptin, which as mentioned above has been shown
to clear the liver of excess lipid under various adverse
circumstances. If leptin does not decrease hepatic lipid
size and content in the presence of IOP treatment, then T3

or some other factor regulated by T3 may be important in
helping to facilitate the breakdown of lipids in the liver.

If leptin does decrease hepatic lipid size and content in
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the presence of IOP treatment, then T3 is not important in

aiding leptin to export lipids, supporting the vital
importance of leptin being able to function during

stressful conditions. It is also expected that adipocyte
areas will be large in leptin treated mice and in IOP
treated mice, compared to vehicle treated mice, with IOP

treated mice possibly having the largest cells. This could

be expected because leptin treatment should reduce liver
lipid and store it in adipose cells until utilized in

metabolism. If oxygen consumption rates are increased in
the leptin treatment, then adipocyte areas should be

decreased due to an increased use of adipocytic lipid in
metabolism. IOP treated mice should have large adipose

cells because of the extreme lipid storage in the liver and

adipose tissue and decreased oxygen consumption rates
previously observed in this treatment. The leptin/IOP

treated mice should express smaller adipocytes than vehicle
treated mice, but it is not known if leptin can

successfully increase metabolism in a low T3 environment or
how the size of those adipocytes will compare to the mice
in the leptin and IOP single treatments.

In this thesis, in order to study the effects of

leptin under both normal and reduced T3 concentration,
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C57BL/6J ob/ob mice were treated for seven days with either

vehicle, leptin, IOP, or a combination of leptin/IOP. These

treatments should have resulted in mice with T3 alone
(vehicle) , leptin 4- T3 (leptin treated) , neither leptin nor

T3 (IOP treated), or leptin alone (leptin/IOP treated).
These mice were analyzed for changes in total mass-specific

oxygen consumption, body weight, substrate used in

metabolism, and food intake over the seven day period.
Additionally, end point analyses determined omental and
subcutaneous adipocyte area and hepatic lipid content and

LD size.
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CHAPTER TWO

THE EFFECTS OF LEPTIN AND THYROID HORMONE ON

METABOLISM AND LIPID TRAFFICKING IN THE
LIVER AND ADIPOSE TISSUE

OF OB/OB MICE

Introduction

With obesity becoming a world-wide epidemic, it is
imperative to understand the pathology associated with
obesity. Obesity is result of the altered control of

hormones regulating metabolic glucose and lipid trafficking
pathways (such as leptin and thyroid hormone)(Houseknecht

1998) . The actions of these hormones are targeted as
possible routes of therapy to control obesity and its
complications. Leptin is a hormone secreted by adipose

tissue in response to fluctuation in cellular energy

reserves (Tartaglia et al. 1995). Its main role is to act
as an appetite inhibitor when enough "energy" has been
taken in. Leptin deficiency would reduce feeding inhibition

and, therefore, promote obesity. The thyroid hormone
3,5,3'-triido-L-thyronine (T3) regulates lipogenesis,

lipolysis, fat storage, and basal oxygen consumption

rate(Oppenheimer 1991). Since T3 induces an increase in
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metabolism, which primarily utilizes fatty acids stored in

adipose tissue, the hormone also induces the production of

lipids, allowing a reserve to be maintained for the
increased oxygen consumption rate that results from the
increased metabolism (Oppenheimer 1991). Low levels of

thyroid hormone can lead to a decrease in lipolysis, which

would lead to an increase in body fat stores in adipose
tissue, and low T3 is associated with low metabolic rate,
low body temperature, slow heart rate, and weight gain

(Hadley 2000). Leptin and thyroid hormone are thought to

interact to control energy homeostasis, but the exact
interaction(s) is unknown.

Pathologies associated with obesity and diabetes are
often linked to leptin deficiency or leptin resistance. The

ob/ob mice of strain C57BL/6J are leptin deficient and thus
provide a good model to investigate abnormalities related
to leptin deficiency. Exogenous leptin replacement in ob/ob

mice has been shown to increase total body energy
expenditure, decrease food intake, and normalize body
weight (Halaas et al. 1995; Maffei et al. 1995). However,
the exact mechanisms leading to these responses are poorly

understood.
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Thyroid hormone regulates physiological pathways
involved in metabolism (including lipid metabolism),
whereas leptin acts to maintain the balance between

.circulating lipid and glucose levels and the quantity
stored in various tissues. This suggests that these two
hormones may interact to affect lipid storage and

disruption of this interaction may lead to the development
of obesity. In this thesis, the possible cross-effects of
leptin and thyroid hormone in obesity were studied in

leptin deficient ob/ob mice. Individuals were administered
iopanoic acid (IOP) to reduce thyroid hormone
concentrations, and leptin, to rescue leptin deficiency.

Reducing T3 will allow us to assess leptin's ability to

increase body energy expenditure, decrease food intake, and
normalize body weight in the presence of low T3

concentrations. The following changes were assessed in mice

given leptin, IOP, or a combination of both: oxygen
consumption, respiratory quotient values, food consumption,
percent body weight change, omental and subcutaneous

adipocyte sizes, and hepatic lipid droplet content and

size.
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Methods

Twenty 9 week old female mice, strain C57BL/6J ob/ob

(Jackson Laboratory), were used to analyze variation in
metabolic expenditures in response to four different

treatments. Five animals per treatment group were used for
data analysis (previously shown to be an adequate sample

size for statistical significance).
The mice were housed individually in a 12:12

light-.dark cycle and allowed access to food ad libitum. On
the morning of day zero, all mice were given a known

quantity of normal rodent chow (4% fat). Variation in food
intake during the treatment period was calculated by

subtracting the amount of food remaining from the previous
day's amount. Each mouse was weighed and placed into an
individual chamber of a flow-through metabolic system

(AMETEK, AEI Technologies; S-3A/II oxygen and CD-3A carbon
dioxide analyzers). Air was pulled out of each chamber at
400 ml/min and analyzed for the fraction of oxygen and

carbon dioxide content. Excurrent air was passed through
desiccant to remove any moisture. Each mouse was allowed to

settle in the chamber for five minutes prior to data

collection. Readings for each animal were taken in the
morning (between 06:00- 09:00 hours). Each animal was
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sampled three times over a 24 miniate period, and the

average value was used in subsequent analyses. During the
reading period, the mice were observed for relative
activity levels that may have affected metabolic readings
and any behavioral responses to the treatments were

recorded. Mass specific metabolic rate (total oxygen

consumption) was calculated as:

Vo2~ (F02 in ~ F02 out) V
Mb

•

V02 = the measurement of oxygen uptake, expressed as a

volume of consumed 02 per minute per gram body mass,
•

F02 in = fraction of O2 in the air entering the chamber,

•

Fq2

out = fraction of O2 in the air exiting the

chamber,
•

V = the flow rate of air moving through the chamber
(ml/min)

•

Mb = body weight (g)

Respiratory quotient (RQ) is a measure of metabolic

substrate use and can range from 0.71 (lipid utilization)
to 1.0 (carbohydrate utilization); an RQ of around 0.80

suggests protein utilization. The RQ value is affected by
the differences in the amount of energy required to consume
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a lipid, protein, or carbohydrate, as well as the chemical

balance of carbon, hydrogen, and oxygen atoms in the

consumption equation. The RQ was calculated as:

RQ =

(Vco2)/(VO2)

•

VC02 ~ CO2 production rate

•

Vo2 = O2 consumption rate.
Eight channels on the gas analyzer allowed eight mice

to be sampled at the same time on the same day which
allowed for increased efficiency in gathering results as

well as consistency. Due to the relatively constant

conditions in the animal house, readings done during
separate time frames would not affect the results because

they were both done in the morning.
There were five ob/ob leptin deficient mice per group

in each of the following treatments: vehicle (control for
handling and injecting mice), leptin (to rescue leptin
deficiency) , IOP (to effectively lower concentrations of

T3), and leptin/IOP (to observe the affects of leptin in the

presence of low T3) .

(See appendix B for recipes.) Each

animal was inj ected intraperitoneally (I.P.) with its
respective drug treatment after the completion of all

metabolic readings.
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The metabolic analyses and injections were carried out

over eight consecutive days during the same morning hours
to control for diurnal variation. Each day, before any

analysis was done, each animal was checked to ensure that
no adverse affects were seen due to the treatments. If any

mouse had symptoms, including extreme exhaustion and
listlessness, then it was removed from the colony and dealt

with according to IACUC protocols. This was done in
addition to observing activity levels during the reading

periods.

On the eighth day, all of the afore-mentioned
procedures were carried out with the exception of the
injections. After morning analyses were complete, all of
the mice were euthanized with CO2 for tissue collection.

Blood (ca. 1.0 ml) was collected via cardiac puncture after
ventilatory arrest, but just prior to cardiac arrest, and
stored on ice until centrifuged after the dissections. The
plasma was stored at -80°C. Three pieces (approximately 1

mm3 each) of the lower left lobe of the liver from each
mouse were extracted and fixed in 2.5% glutaraldehyde with

Tyrode's Cacodylic acid for TEM embedding (see appendix C).
The remainder of the liver was frozen and stored in liquid
nitrogen. Omental and subcutaneous adipose tissues were
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frozen and stored in liquid nitrogen until analysis of cell

cross-sectioned area. Small pieces (size irrelevant) of the

omental and subcutaneous adipose tissues were taken, placed
on a microscope slide, stained with methylene blue, and

examined and photographed using light microscopy at 200x
magnification.

Multiple images were captured per slide

using NIH Image and later analyzed for adipose cell areas

using ImageJ. Ten cells per tissue were analyzed, and the

average cell cross-sectioned area was taken as
representative.

Size and distribution of liver lipid droplets were

analyzed using the TEM embedded tissues. The osmium

tetroxide fixative stains the lipids black and allows for
analysis of lipid content. The tissues were sectioned to a
thickness of 900 nm using an ultramicrotome. The sections

were placed on a microscope slide and examined using light
microscopy at 400x and lOOOx magnification. NIH Image was

used to capture three images per slide per magnification,
and ImageJ was used to determine lipid droplet sizes and
content in hepatocytes.

All data were analyzed using one way analysis of
variance (ANOVA) in Sigma Stat (Systat Software, Inc.

2004). Where relevant, nested ANOVA was performed, i.e.
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lipid droplet size was modeled by group and mouse. This

allowed the data from three separate cross-sections per

mouse to be analyzed for group effects more efficiently.

Pairwise comparisons were done with Tukey's test. Dunn's
test was used to compare multiple points against a control

group. Linear regression analyses were performed between
all variables observed in the study, between groups and

within groups between days. Where relevant, linear
regressions were run with parameters assessed and food

consumption to control for the alterations that might occur

based on eating habits. Post-hoc corrections (Bonferroni)
were done on all data not subjected to Tukey's test. Data

with corrected p values less than 0.05 were considered

significant.

Results/Discussion
Daily Observations

The morning of the first day of injections (day 1),

all of the twenty mice had high activity levels and were

eating normally. By day two, all of the mice in the IOP and

leptin/IOP treated groups were lethargic and had stopped
eating. Two animals from each of those groups died on days
four and five. Since the cause of death from these animals
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is not completely certain, all of the data for those
individuals were omitted from the analyses. The final

sample size per group was as follows: vehicle (veh): 5,
leptin (lep): 5, iopanoic acid (IOP): 3, and

leptin/iopanoic acid (lep/IOP): 3.
Body Mass
To normalize for differences in body weight among all
the mice on day zero (figure 3), body mass change was
analyzed by starting at 100 percent on day zero and either

adding or subtracting percent change for each treatment
group as they either gained or lost weight, respectively.

The body mass of vehicle and leptin treated mice did not

change whereas IOP and leptin/IOP treated mice lost weight
(P < 0.016 and p < 0.008, respectively; figure 4). The mice

in the vehicle group ate steadily every day and showed a

correlation of increased body mass with time (see below).
The lack of weight gain in mice in the leptin group

suggests that leptin inhibited appetite. Ob/ob mice do not

produce leptin and therefore vehicle treated mice can

continue to gain weight. However, the body mass for this
group was not significantly greater from day 0.

The relative change in weight between the mice in the

leptin treatment and leptin/IOP treatment were
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Day 0 vs.

Day 7 Mean Body Weight
#

Figure 3. Day 0 vs. Day 7 Mean Body Weight. Statistica
analyses show that IOP and leptin/IOP treated mice
weighed less on day 7 than vehicle treated mice.
Leptin/IOP treated mice also weighed less than leptin
treated mice.
*Significant differences in body mass of the groups
compared to the vehicle treated group.
#Also significantly different was leptin vs.
leptin/IOP; p < 0.05
Values are mean ±SEM. For vehicle and leptin, n=5. For
IOP and leptin/IOP, n=3.

significantly different from each other after seven days (p

< 0.008), while no other combinations revealed significant
differences among one another. The vehicle and leptin/IOP

treated mice showed a significant relationship between

change in body mass and day of trial (r2= 0.959, p< 0.04 and

r2= 0.997, p< 0.024, respectively; figure 5). The leptin
treated mice did not fluctuate in weight during the study
(r2= 0.0072, p < 0.928). The IOP treated mice lost weight
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Percent Change in Body Weight After 7 Days

B

p values from ANOVA results and Tukey's test

Vehicle
Leptin
IOP
Leptin/IOP

Vehicle

Leptin

0.110
0.016
0.008

0.392
0.008

IOP

Leptin/IOP

0.228

Figure 4. Percent Change in Body Weight After Seven Days
of Treatment. Data are normalized to body mass on day 0.
A. Vehicle and leptin treated mice showed no difference
in weight change during the treatment period, while the
IOP and leptin/IOP treated mice lost weight.
B. p values from ANOVA results and Tukey's Test.
*Significant differences of percent weight change in the
groups compared to the vehicle treated group after the
treatment period.
#Also significantly different was leptin vs. leptin/IOP;
p < 0.05
Values are mean ±SEM. For vehicle and leptin, n=5. For
IOP and leptin/IOP, n=3.

during the first three days, likely due lack of food

consumption associated with treatment, but by day four, two
of the three mice still alive recovered and were gaining
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B

Linear Regression Results
r2
F
P

Vehicle
0.515
40.4
0.04*

Leptin
0.00720
0.00826
0.928

IOP
0.313
10.0
0.096

Leptin/IOP
0.950
417
0.024 *

Figure 5. Percent Weight Change Per Day of Treatment.
A. Vehicle treated mice showed a tendency of increasing
body weight over the treatment period. Leptin/IOP treated
mice showed a tendency of decreasing body weight. Leptin
treatment did not affect weight during the treatment period
and IOP treated mice showed no tendency of either
decreasing or increasing weight. The equations of the lines
for the vehicle, leptin, IOP, and leptin/IOP groups were as
follows: y= l.llx + 99.08, y = -O.Olx + 100.1, y = -1.27x +
96.18, and y = -3.25x + 99.20, respectively. For vehicle
and leptin, n=5. For IOP and leptin/IOP, n=3.
B. Table of r2, F, and p values from linear regression
analyses of daily percent weight change versus day of
treatment.

weight. Given that one mouse in this group did not show the
same trend and given the small sample size, the body weight
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for this group is not strongly correlated with day of
treatment (r2= 0.683, p < 0.096).

Food Consumption
Daily food consumption was analyzed to detect the
effects of the treatments on the regulation of appetite.

Analysis of food consumption began after the first
treatment day; therefore, there are no data for pre
treatment food consumption; however, food consumption was

determined daily for the time during the treatment.
The body mass normalized average daily food

consumption was significantly lower in the IOP and

leptin/IOP treated mice relative to control mice (p < 0.05;
figure 6). Furthermore, the leptin/IOP treated mice
consumed less food than the leptin and IOP treated mice.

Since the IOP and leptin/IOP treated mice became ill, the
decreased food consumption seen in these groups may not be

from the treatments directly but due to illness. Some of
the animals in the IOP group recovered after day three and

started eating again, but one mouse in this group did not
eat during the entire treatment period. Therefore, the

small sample size (n=3) may be a factor as to why decreased
food consumption was observed counter to expectations.
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Figure 6. Mass-Specific Mean Daily Food Consumption. Mean
daily food consumption per body weight showed that the IOP
and leptin/IOP treated mice ate less on average per day
than the vehicle and leptin treated mice. Although, a
slight decrease in food consumption is seen in the leptin
treatment, this was not significant.
^Significant differences with groups against the vehicle
treated group.
#Also significantly different were leptin vs. leptin/IOP,
IOP vs. leptin/IOP; p < 0.05.
Values are mean ±SEM. For vehicle and leptin, n=5. For IOP
and leptin/IOP, n-3. MB = body mass weight

The mean food consumption after the seven day treatment

period varied between all groups. Leptin treated mice ate

less total food than vehicle treated mice, but this was not
significantly different. However, total food consumed by

both the IOP and leptin/IOP treated mice was significantly

less than food consumed by vehicle treated mice (p < 0.05,
data not shown). On day one of treatment, the IOP and
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leptin/IOP treated mice ate less food than vehicle treated

mice (p < 0.05, figure 7). Only the vehicle treated mice
significantly changed their rate of food consumption over
the study period (p < 0.05, figure 7). However, the
remaining IOP treated mice did start eating more after the

fourth day of treatment and, therefore, have a higher mean
food consumption on day seven. While the difference is not

significant between day 1 and day 7 food consumption for
IOP treated mice, it can be supported by the relationship

between food consumed and day of trial (see below).
Vehicle and IOP treated mice increased mean daily food

consumption over the seven day treatment period (p < 0.005
and p < 0.015, respectively; figure 8). This suggests that
the IOP treated mice may have been moving towards the same

or greater rate of food consumption as the vehicle treated

mice. Therefore, the initial low amount of food consumption
seen in the IOP group may have been because the animals in
that group were sick and not because of the effects low T3.
The leptin and leptin/IOP treated mice showed no trends

towards changing food consumption as a result of their
treatment.
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Day 1 vs. Day 7 Mean Food Consumption

■ Day 1
EDay 7

*

*

Lep/lOP

Treatment Group

Figure 7. Mean Daily Food Consumption on Days 1 and 7 of
the Treatment Period. Compared to vehicle treated mice,
the IOP treated mice ate less food on day 1, and
leptin/IOP treated mice ate less on day 1 and day 7. On
day 7, the leptin treated mice consumed less food
compared to the vehicle group, but this was not
significant.
#Significant difference between food consumption on day
1 and day 7.
*Significant differences with groups relative to the
vehicle treated group for the same day. Also
significantly different on day 1 were leptin vs.
leptin/IOP, leptin vs. IOP and on day 7 were leptin vs.
leptin/IOP, leptin vs. IOP; p < 0.05.
Values are mean +SEM. For vehicle and leptin, n=5. For
IOP and leptin/IOP, n=3.

Oxygen Consumption and RQ

Metabolic rates were determined daily using a flowthrough metabolic system. There were no differences in
mass-specific oxygen consumption between any of the

treatment groups on day 7 (figure 9). All groups maintained
an approximately constant average rate of oxygen
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Linear Regression Results

F

E

Vehicle
0.286
13.22
0.005 *

Leptin
0.135
5.135
0.150

IOP
0.372
11.27
0.015*

Leptin/IOP
0.0013
0.0247
0.877

Figure 8. Mass-Specific Daily Food Consumption.
A. Trend of average food consumption throughout the seven
day treatment period. The vehicle and IOP treated mice
showed a tendency of increasing mean daily food consumption,
p < 0.005 and p = 0.015, respectively, while the leptin and
leptin/IOP treated groups showed no change over the 7 day
treatment period. The equations of the lines for the
vehicle, leptin, IOP, and leptin/IOP groups were as follows:
y = 0.0096x + 0.0766, y = 0.0033x + 0.0743, y = 0.0142x 0.0106, and y = -7E-05x + 0.0019, respectively.
Mb= body weight
Values are mean. For vehicle and leptin, n=5. For IOP and
leptin/IOP, n=3.
B. r2, F and p values of the treatment groups for linear
regression analysis of trends during the seven day treatment
period.
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Figure 9. Oxygen Consumption on Days 0 and 7 of the
Treatment Period. On day 0, leptin and IOP treated mice
consumed less oxygen than vehicle treated mice (p < 0.007
and p < 0.012, respectively). There were no differences
compared to vehicle treated mice for any groups on day 7.
Leptin treated mice consumed more oxygen on day 7 than on
day 0.
*Significant differences with groups relative to the
vehicle treated group for the same day.
#Significance on day 0 vs. day 7 for lep, p < 0.05.
Values are mean ±SEM. For vehicle and leptin, n=5. For
IOP and leptin/IOP, n-3.

consumption (0.030 ± 1.6 x 10"3 ml02-min-1 *g-1) during the
seven days. Surprisingly on day zero, leptin treated mice

and IOP treated mice had lower mass-specific oxygen

consumption rates than vehicle treated mice (p < 0.007 and
p < 0.012, respectively; figure 9). Leptin treated mice

also consumed more oxygen on day 7 than on day 0 (p <

0.012). Eating, time of day, and activity levels are all
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known to affect rate of oxygen consumption. Since day zero
was before any treatment, all of the oxygen consumption

rates should have theoretically been similar since all of
the mice exhibited similar eating and activity patterns on
day zero, and the metabolic tests were.done at the same

time. Therefore due to the variability observed, these data

may not be accurate.
The ratio of CO2 production to O2 consumption (RQ)

changes based on the substrate being oxidized and thus may
allow for a better understanding of lipid and glucose
trafficking. The RQ for the leptin treated mice decreased

over the seven day treatment period (p < 0.015), while the
RQ of other groups did not show any change on a day- to-day
basis (data not shown). On day 7, the leptin and IOP

treated mice had lower RQ values compared to day zero (p <
0.016 and p < 0.048, respectively; figure 10). No other

groups had significantly different RQ values between day 0
and day 7. Compared to vehicle treated mice on day 7,

leptin/IOP treated mice had a lower RQ indicative of lipid
metabolism (figure 10). It is not known if this was a
treatment affect. The lower RQ may have been due to the

fact that animals from this group did not eat so their only

source of energy would have been reserves in adipose
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Day 0 vs. Day 7 Mean Respiratory Quotient
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Figure 10. Respiratory Quotient (RQ) on Days 0 and 7 of the
Treatment Period. On day 0, IOP treated mice had an RQ
higher than the vehicle treated mice. On day 7, vehicle,
leptin, and leptin/IOP treated mice had an RQ of about
0.85. This suggests that the mice were utilizing a mixture
of carbohydrates and lipids to fuel metabolism. Leptin/IOP
treated mice had an RQ of 0.79 after the treatment period,
suggesting these mice were utilizing mostly lipids in
metabolism.
^Significant difference on day 0 for vehicle vs. lep and
vehicle vs. IOP, and day 7 for vehicle vs. leptin/IOP. Also
significant on day 7 was leptin vs. leptin/IOP.
#Significance on day 0 vs. day 7, p < 0.05.
Values are mean ±SEM. For vehicle and leptin, n=5. For IOP
and leptin/IOP, n=3.

stores. The leptin and IOP treated mice had RQ values

similar to that of the vehicle treated mice after seven
days, all of which were indicative of a mixture of both
carbohydrate and lipid metabolism. As with oxygen

consumption, day zero RQ was highly variable (1.05 + 0.12)
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among the mice even though this was pre-treatment.

Therefore, experiments on RQ need to be repeated to
understand the implications of RQ from these drug

treatments.
Adipose Tissue

Omental adipose tissue is found near the stomach and

spleen and can extend into the rest of the abdominal
cavity. Adipocyte sizes fluctuate depending on nutrient

availability. Relative to vehicle treated mice, leptin
treated mice had larger adipocyte areas (p < 0.05),

leptin/IOP treated mice had smaller adipocyte areas (p <
0.05), whereas the IOP treated mice were not different from
vehicle treated mice (figure 11A, 12). It is not known

whether the decrease in adipocyte area for the leptin/IOP
treated mice was due to reduced food consumption or to the

treatment. The leptin/IOP treated mice would have been
expected to have adipocyte areas in between those of leptin

and IOP treated mice, not lower, suggesting that the
results seen for this group are due to starvation. During

starvation, lipids stored in adipocytes are metabolized to
support whole-body energy consumption.
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A

Omental Adipocyte Area

B

Subcutaneous Adipocyte Area

Figure 11. Omental and Subcutaneous Adipocyte Area.
A. Omental adipocyte area among the different
treatment groups. Relative to vehicle treated mice,
leptin treated mice had larger adipocyte areas, IOP
treated mice had similar adipocyte areas, and
leptin/IOP treated mice had smaller adipocyte areas.
B. Subcutaneous adipocyte area among treatment
groups. Subcutaneous adipocyte area in the
leptin/IOP group decreased compared to the vehicle
group. Leptin and IOP treated mice had cell sizes
similar to that of vehicle treated mice.
*Significant differences relative to vehicle treated
mice. #Also significantly different were in A:
leptin vs. leptin/IOP; in B: leptin vs. leptin/IOP,
p < 0.05. Values are mean ±SEM. For vehicle and
leptin, n=5. For IOP and leptin/IOP, n=3.
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Figure 12. Omental Adipose Tissue Viewed Under the
Light Microscope.
A: vehicle treated mice; B: leptin treated mice; C: IOP
treated mice; D: leptin/IOP treated mice. Leptin
treated mice had the largest adipocyte area, leptin/IOP
treated mice had the smallest, and IOP treated mice had
similar adipocyte area relative to vehicle treated
mice.
Ten different fields of view were taken per animal at
200x.

Subcutaneous adipose tissue is the fat storing tissue
found just beneath the surface of the skin. This fat is

mainly used for insulation and long-term storage of lipid.
Subcutaneous adipose stores are the primary source for

lipids utilized during starvation; however, omental adipose

stores can still be used (Wajchenberg 2000). However, there
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were no significant correlations observed between omental
adipocyte area and relative weight change.

The large omental adipocytes observed in leptin

treated mice may be indicative of lipid be taken away from

peripheral tissues that may have exhibited excess fat
before treatment (because they are obese), but with leptin

treatment they are able to redirect the lipid to omental

adipose tissue for temporary storage. IOP treatment had no
effect on the average area of individual adipocytes,

suggesting that low thyroid hormone does not affect lipid

storage in omental fat.
The leptin/IOP treated mice had the smallest area per

cell in subcutaneous adipocytes; these mice had
significantly smaller cells than both the vehicle and

leptin treated mice (p < 0.05, figure 11B, 13D). The area
of subcutaneous adipocytes in IOP treated mice was not
different from either vehicle or leptin treated mice
(figure 13).

The subcutaneous adipocytes in mice in the leptin/IOP

group may have been acting as the primary energy source for
these mice because they did not eat during the treatment

period. This idea could be supported by a positive

correlation between mean daily food consumption
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Figure 13. Subcutaneous Adipose Tissue Viewed Under the
Light Microscope.
A: vehicle treated mice; B: leptin treated mice; C: IOP
treated mice; D: leptin/IOP treated mice. Leptin and
IOP treated mice had similar adipocyte areas to vehicle
treated mice, while leptin/IOP treated mice had a
smaller adipocyte area.
Ten pictures were taken per animal at 200x.

(g food/day/g Mb) and subcutaneous adipocyte areas in the
leptin/IOP group; however this relationship turned out to

be insignificant (p = 0.093, r2 = 0.998, F = 416) because

food consumption was about zero for these mice. These two
variables were not correlated in any other group.

The average area of subcutaneous adipocytes in the

leptin and IOP treated mice did not change relative to the
vehicle mice. It was hypothesized that IOP treated mice
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would show an increase in the subcutaneous adipocyte area
because low levels of thyroid hormone reduce lipolysis

(Oppenheimer 1991; Pou 1989). Since the mice in this group

were sick at the beginning of the study, the area of the
adipocytes may have decreased as these cells were providing
lipids for energy. As these mice started eating again, the

cell area increased. The mice treated with leptin were
expected to have a decrease in subcutaneous adipocyte area

as leptin acts to stimulate lipolysis and induce weight

loss in obese mice (Halaas et al. 1995; Maffei et al.
1995). The results support the idea that subcutaneous lipid

is primarily metabolized when energy supply is low. Since
food was available and mice in the vehicle, leptin, and IOP
groups all ate, their subcutaneous adipocyte area remained
the same.

Hepatic Lipids
The liver stores lipids in small intracellular

droplets. Both the size of the droplet and the total amount

of lipid in the cell vary with metabolic demand. Total
hepatic lipid droplet (LD) content was determined by

calculating the cross-section area of LD in a cell (figure

14). It was seen that leptin treated mice had the least
amount of lipid while leptin/IOP treated mice had the most
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Figure 14. Hepatic Lipids Viewed Under the Light
Microscope.
A: vehicle treatment; B: leptin treatment; C: IOP
treatment; D: leptin/IOP treatment. Compared to vehicle
treated mice, leptin treated mice had less, and leptin/IOP
treated mice had more, hepatic lipid, while hepatic lipid
in IOP treated mice was similar.
TEM embedded, osmium tetroxide post-fixed livers sectioned
at 900 nm and viewed at lOOOx.

(p < 0.05; figure 15). The IOP treated mice had relatively
similar lipid content as the vehicle treated mice.

Moreover, hepatic cells from both the leptin treated mice
and IOP treated mice contained significantly less lipid

than those cells from the leptin/IOP treated mice (p <
0.05).
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vehicle treated mice, leptin treated mice had less
lipid droplet content, IOP-treated mice had the
similar amounts of lipid droplet content, and
leptin/IOP treated mice had more lipid droplet
content.
*Significant differences with groups against the
vehicle treated group. #Also significantly
different were leptin vs. leptin/IOP, IOP vs.
leptin/IOP; p < 0.05.
Values are mean ±SEM. For vehicle and leptin, n=5.
For IOP and leptin/IOP, n=3.

I predicted that a treatment combining leptin and IOP

should result in a metabolic profile similar to leptin
treatment alone. The hepatocyte lipid content seen in the
present study showed that leptin treatment caused a
reduction in the amount of total lipid in the liver where
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IOP treatment of leptin-deficient mice caused no change in
lipid content, confirming previous research (Reno and Fehn
2007) . The results from the leptin/IOP treatment were

contradictory to expected. The total lipid content in the

liver actually increased; therefore, the prediction that
leptin would rescue steatosis in mice with a low thyroid
hormone concentration was shown to be incorrect. This

suggests that thyroid hormone may be an important factor
involved in controlling hepatic lipid breakdown and/or

export, as supported by Mukhopadhyay et al.

(2003).

Hepatic LDs were categorized into two groups: small (<
100 pm2) and large (> 100 pm2) , as done previously (Reno and

Fehn 2007), because these are arbitrarily the two main

groups of lipid droplets in the liver. All of the
treatments caused a large number of small LDs in the liver,

most likely because all mice are synthesizing lipid, just
at various rates. Furthermore, the sizes of individual LDs
within the < 100 pm2 class were all different among the

groups (p < 0.05; figure 16A) . IOP treated mice had smaller
LDs than the vehicle treated mice, while the LDs in leptin
and leptin/IOP treated mice were larger than the vehicle

treated mice.
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Figure 16. Small Liver Lipid Droplets.
A. Analysis of small LDs showed that leptin, IOP, and
leptin/IOP treated mice had small LDs of different sizes
compared to the vehicle group. Of all the small LDs, the
leptin/IOP group had the largest LDs and the IOP group
had the smallest. The leptin group had larger LDs than
the vehicle group.
B. Total small liver LD area covered. Leptin treated
mice showed more small LDs relative to vehicle treated
mice. IOP and leptin/IOP treated mice had livers covered
in similar amounts of small LDs to vehicle treated mice.
^Significant differences against the vehicle treated
group. #Also significantly different were in A: leptin
vs. IOP, leptin vs. leptin/IOP, IOP vs. leptin/IOP; in
B: leptin vs. IOP, IOP vs. leptin/IOP, p < 0.05.
Values are mean ±SEM. For veh and lep, n=5. For IOP and
lep/IOP, n=3.
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The various small LDs seen within the small size
category are thought to be indicative of lipid synthesis,

but also could be representative of the breakdown of larger
(> 100 pm2) LDs for lipid export. Leptin treated mice were

expected to have the smallest LDs of all the groups and
leptin/IOP treated mice to have slightly larger LDs because
the effects of low T3 would cause less hepatic lipid

breakdown, leading to larger LDs (Mukhopadhyay et al.

2003). LDs in IOP treated mice were not expected to change
from those in vehicle treated mice. Even though all groups
had small LDs, the total areas of a cell covered by small

LD's were different. The visual analyses were supported by

a nested ANOVA (figure 16B). The hepatocytes of leptin
treated mice had the most area covered by small LDs while
the hepatocytes covered by small LDs in IOP and leptin/IOP

treated mice were not different relative to the vehicle
treated mice. However, the IOP treated mice had less

hepatic area covered by small LDs relative to leptin and

leptin/IOP treated mice (p < 0.0002 and p < 0.016,
respectively). The livers of IOP treated mice may have had
smaller small LDs because their livers contain mostly large
LDs (discussed below), which indicates lipid storage. While
the small LDs are present in all groups, they may not be as
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important in understanding hepatic lipid content as large
LDs (see below).

Within the class of LD > 100 pm2, leptin treated mice
had the smallest LD (mean= 200 pm2, p < 0.05; figure 17A) .
The large LDs in this class from the TOP and leptin/IOP

treated mice were also significantly larger than those of
the leptin treated mice (p < 0.05), but not from one

another or the vehicle treated mice.
The fact that livers of leptin treated mice had the

smallest LDs within the large LD class once again suggests

leptin acts to decrease the size of these larger LDs in
obese mice, breaking them down for export and/or (5-

oxidation. In leptin treated mice, small LDs (mean= 15 pm2)
predominated over large LDs (mean= 200 pm2) . It was not

expected that LDs in the IOP and leptin/IOP groups would be
about the same size as those of the vehicle treated mice.

However, while the average size of these storage droplets

may be relatively similar, the total area taken up by large
LDs was different between the groups (figure 17B). The area

covered by large LD in IOP treated mice was a similar

amount to vehicle treated mice, but significantly greater

than the leptin treated mice (p < 0.0007). The leptin/IOP

treated mice had more area covered by large LDs than all
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Figure 17. Large Liver Lipid Droplets.
A. Large liver lipid droplets show that the leptin
group has the smallest lipid droplets in the large LD
group. The IOP and leptin/IOP groups had lipid
droplets not different from the vehicle group.
B. Total large liver LD area covered. Leptin treated
mice had less hepatic large LDs, while leptin/IOP
treated mice had more hepatic large LDs than vehicle
treated mice. IOP treated mice had similar area
covered in liver with large LDs relative to vehicle
treated mice.
^Significant differences against the vehicle treated
group.
#Also significantly different were leptin vs. IOP,
leptin vs. leptin/IOP, p < 0.05. Values are mean ±SEM.
For vehicle and leptin, n=5. For IOP and leptin/IOP,
n=3.
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other groups (p < 0.00001). The inability of leptin/IOP

treated mice to break down the large LDs suggests that the
action of leptin was hindered, possibly by the lack of

thyroid hormone.
Taken together, the quantity and sizes of hepatic LDs

suggest that while leptin treatment alone can reduce large
LDs, the leptin/IOP combined treatment cannot. The greater

total lipid content and the larger LDs observed in the
leptin/IOP group provide more evidence for a possible

leptin/thyroid hormone interaction. As mentioned earlier,
j
previous research (Reno and Fehn 2007) suggests leptin has
the ability to reverse the effects of obesity during

adverse conditions, such as sympathetic neuron ablation and

hyperthyroidism, whereas a low thyroid hormone environment

in obese mice causes massive hepatic steatosis. Although
IOP treated mice did not have more lipid or larger LDs than

the vehicle group in this study, the hepatic lipid content

in both of these groups is still very high (about 60-80%

more lipid than a normal (ob/+) mouse). Since leptin
replacement in conjunction with IOP did not decrease the
quantity or size of the lipids as it does when given alone,
the lowered T3 levels are likely inhibiting the action of

leptin. Thus thyroid hormone may be an essential factor
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that works in concert with leptin to regulate hepatic lipid

trafficking (i.e. T3 may be permissive to leptin).

Conclusion
The effects of leptin and thyroid hormone on various

metabolic parameters were studied in leptin-deficient obese

mice. Exogenous leptin decreased liver lipid content,
reduced liver lipid droplet sizes, and increased the size

of omental adipose cells. All of these results confirm
previous studies showing leptin has the ability to reduce

excess lipid storage in the liver by shuttling lipid to

adipocytes. Although the IOP and leptin/IOP treated mice

became ill, this experiment still provides insight into the
role of thyroid hormone in lipid trafficking. IOP treatment

alone produced results similar to the control mice with

regards to lipid storage in adipose tissue and liver, and
the leptin and leptin/IOP treated mice showed opposite

results to one another. Therefore, comparisons among the
leptin, IOP, and leptin/IOP groups can still be made. The
IOP treated mice were not different from the vehicle

treated mice with regards to adipose tissue and liver lipid

storage. Oddly, when leptin and IOP were combined,
significant decreases were seen in omental and subcutaneous
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adipocyte areas and increases in liver lipid content, which

indicated excess lipid storage. This is surprising because
my working hypothesis was that giving leptin to an obese
animal in a low thyroid hormone environment should produce

results that reflect a reversal of excess lipid storage
that occurs in the IOP treatment alone. The mice in the

combined leptin/IOP treatment actually had increased
hepatic lipid content and lipid droplet size, but had the

smallest adipocyte areas. The hepatic lipid should have
been exported and lipid storage should have taken place in
adipose tissue only. Since this occurred in the leptin

treated mice and did not occur in the IOP treated mice,
this suggests lack of thyroid hormone is the limiting

factor regarding the ability to export hepatic lipids or to
use them for 0-oxidation.

Thyroid hormone is an important regulator of
metabolism, and this study provides further evidence that

it is essential in lipid trafficking in the liver. Further

studies should be conducted that analyze thyroid hormone
effects in other tissues to obtain a better picture of its
role in whole-body metabolism. Further study is also needed

to understand the role of thyroid hormone in the export
mechanisms of hepatic lipids, especially the proteins that
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may be involved in LD breakdown, export, and/or poxidation.
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CHAPTER THREE

DISCUSSION OF CONCLUSIONS COMPARED

TO PREVIOUS WORK

Discussion

In the present study, leptin-deficient obese mice were
used to study how the hormone leptin acts on lipid
metabolism in a low thyroid hormone environment. Metabolic

parameters examined were food consumption, weight change,
mass-specific oxygen consumption, respiratory quotient

(RQ), omental and subcutaneous adipocyte areas, and hepatic
lipid content and size.

Metabolic rate can be estimated from the rate of
oxygen consumption (V02) • Metabolic rate can be affected by

numerous factors, including food intake, activity levels,
and time of day. This study attempted to minimize variation

in metabolic rate from these factors. All of the animals
were allowed access to food day and night while in their

cages. While in the metabolic flow-through chambers, all

animals did not have access to food and their relative
activity levels were noted. All mice were in the chambers
for approximately eight minutes before measurements were

taken to acclimate them to unfamiliar surroundings.
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Furthermore, the metabolic rates were measured in the early
morning hours every day. However, in spite of attempting to

minimize these variations, there were large differences in
pre-measurement food consumption and relative activity

levels in the chambers.
Mass-specific oxygen consumption was highly variable
among all twenty mice (even on day zero) before any

injections were given. The RQ values were similarly
variable. Due to this variation, the data from both oxygen

consumption and RQ are suspect. However, all mice had a
similar rate of mass-specific oxygen consumption on day
seven. The RQ values on day seven were also similar (RQ =

0.86 ± 0.012) for all groups except leptin/IOP treated
mice, which had a lower RQ (0.78), suggestive of
metabolizing lipids. These mice had not eaten over the
whole treatment period and stored lipids would have been

their only source for energy. The rest of the groups had

similar RQ values indicative of a mixture of lipid and

carbohydrate metabolism.
Leptin is known to suppress appetite, increase
metabolic rate, and cause an obese mouse to lose weight
(Halaas et al. 1995; Maffei et al. 1995). The leptin

treated mice in the current study did not decrease food
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consumption during the treatment period compared to vehicle
treated mice. However, closer examination of the data

suggest that if the treatment had been continued over a
longer period the leptin treated group would have exhibited
significantly decreased food consumption. Unpublished work

from Dr. Fehn's lab suggests that a leptin effect on food

consumption becomes evident after nine' days of treatment.
This is supported by the difference in food consumption

between vehicle and leptin treated mice shown in the trend

line in figure 8. Furthermore, leptin treated mice did not
decrease in body mass during the treatment. However, the
vehicle treated mice did gain weight; therefore, leptin may

have been acting to inhibit weight gain. Mean daily food

consumption by the leptin treated mice was strongly
correlated to final weight change on day seven. Leptin may
have caused a reduction in food intake relative to control

mice, which, in turn, reduced how much weight they gained.

Terminal analysis of omental adipose tissue and
hepatic lipids showed that leptin treated mice had the

largest adipocytes and the lowest hepatic lipid content.

Furthermore, hepatic LDs were mostly small with the largest
LDs still smaller than the other groups' large LDs. Taken

together, these results suggest that leptin promoted the
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breakdown of large LDs in the liver which led to

exportation of the resulting small LDs to the adipocytes or
utilization in p-oxidation. These results agree with those

from previous work on ob/ob mice (Reno and Fehn 2007) .
Since the IOP and leptin/IOP treated mice stopped

eating during the treatment period, starvation effects must

be taken into account during analysis of their data.
Starvation can alter the physiological status of an animal.

During starvation, glucose produced by the liver and
kidneys is primarily used by the central nervous system as

an energy source (Neumann-Haefelin et al. 2004). Fatty
acids released from adipose stores are used for energy by

peripheral tissues, such as heart, skeletal muscle, and
liver. This occurs through fatty acid oxidation and through
the oxidation of ketone bodies, which are by-products of

excess fatty acid breakdown in the liver (Neumann-Haefelin

et al. 2004). Furthermore, acute starvation is known to
cause an increase in secretion of insulin, growth hormone,
and glucagon leading to hypoglycemia (Goodman 1961).

Starvation stimulates adipose tissue to break down
triglyceride to free fatty acids (Goodman 1961). Therefore,
due to the increased lipid mobilization from fat stores,

the respiratory quotient (RQ) should be close to 0.7,
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indicative of lipid metabolism (Von Pettenkofer 1966).

During starvation, metabolic expenditure, i.e. oxygen
consumption, is decreased (Therriault 1968). Therefore, the

mice that stopped eating were expected to have smaller
adipocytes due to starvation alone and not necessarily due

to the effects of the treatments. Moreover, these mice

would be expected to have a lower metabolic rate, which may
cause the lipids released from adipose tissue to accumulate

in other tissues.

Only the leptin treated mice showed a correlation
between mean daily food consumption and body weight, as
well as mean daily food consumption and the size of
subcutaneous adipose cells. However, while the IOP and

leptin/IOP treated mice ate less and lost a relatively
large amount of body weight, there were no correlations
between those variables and either of the groups. The IOP
treated mice most likely did not show a relationship

between the two variables because two of the three mice
that remained in that group started eating and gaining

weight back by day four. The one mouse that did not show
this pattern may have skewed the data. An ANCOVA analysis

of food consumption revealed that this one mouse was

significantly different from the other two in the group.
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However, due to the small sample size, this mouse was not
excluded from the analyses. The leptin/IOP treated mice
stopped eating all together. Thus, there would be no

correlation with weight change because food consumption
stayed at zero throughout the study. Therefore, the

decrease in body mass in the IOP and leptin/IOP groups

cannot be directly attributed to the amount of food (or
lack thereof) consumed.
The leptin treated mice were expected to lose weight,
while the IOP treated mice were expected to gain weight.

Neither of these predicted outcomes occurred. However, the
IOP treated mice which recovered showed a possible trend

towards increasing body mass that may have become
significant given more treatment days. Leptin treated mice

were expected to lose weight. While that result was not
observed, leptin treated mice did have reduced food

consumption relative to the vehicle treated mice, and they
also did not gain weight over the course of the study, like
the vehicle treated mice did.

Despite the prediction that the cross-sectional area
of adipocytes would change with changes in body weight,

omental and subcutaneous adipocyte area were not correlated
with day seven weight change. This suggests that these two
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adipose sites may not be directly affected by acute
fluctuations in body mass, but rather may have a role in
long term energy balance with long term body mass

fluctuations. Moreover, the duration of this study may have
not been long enough to see significant effects.

The size of hepatic LD is indicative of whether the
liver is undergoing lipid synthesis, disposal, or storage.
Large lipid droplets (> 100 pm2) represent a storage form of

lipids, whereas small lipid droplets (< 100 pm2) may suggest

either lipid synthesis, lipid export, and/or p-oxidation.
Understanding how the liver is handling lipids in response

to the different treatments allows for a better
understanding of the lipid trafficking that occurs during
these different conditions. Small LDs were abundant in the

leptin treated mice, suggesting leptin stimulates hepatic
lipid breakdown by p-oxidation and/or lipid export. This is

important because it leads to a reduction in fatty liver
observed in ob/ob mice. Large LDs were abundant in the
vehicle and IOP treated mice, but the livers of leptin/IOP

treated mice had the most area covered by large LDs. It is
not known whether starvation has a major impact on hepatic
lipid trafficking; however, starvation does suppress

hepatic fatty acid synthesis (Kornacker 1965) . The results
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seen in the leptin/IOP treated mice could be due to leptin

induced lipid breakdown, but due to the high hepatic lipid

content in this group, the LDs that are broken down most

likely cannot be exported or undergo |3-oxidation. This
suggests that thyroid hormone may be required to work

either in concert with leptin or independently to export
lipids out of the liver or increase p-oxidation.

Comparison to Previous Work in Dr. Fehn's Lab
Leptin/thyroid hormone interactions have been seen in
previous studies on ob/ob mice (Fehn et al. 1999; Reno and
Fehn 2007) . Ob/ob mice given exogenous leptin increased

thyroid hormone concentration (Fehn et al. 1999). Moreover,

leptin was previously shown to promote hepatic LD breakdown
(Reno and Fehn 2007). Ob/ob mice given excess T3 (thyroid

hormone) in addition to leptin reduced hepatic lipid
content, whereas the absence of leptin in T3 treated mice
resulted in hepatic steatosis. This suggests a possible

interaction between leptin and thyroid hormone influencing
lipid trafficking. Mice given IOP to reduce T3 concentration

showed massive hepatic steatosis. In the present study, IOP
treatment did show hepatic steatosis, but it was to the

same extent as observed in the vehicle group.
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Fehn et al.

(1999) found that omental and subcutaneous

adipocytes were largest in leptin treated mice, and mice in
all other treatment groups had similar adipocyte size. In

the present study, leptin treated mice had the largest

omental adipocytes, whereas leptin/IOP treated mice had the

smallest areas. Vehicle, leptin, and IOP treated mice all

had similar subcutaneous adipocytes while the adipocytes in
the leptin/IOP group were smaller. This supports the idea

that mice use subcutaneous lipid during starvation. There
are no previous data on adipocyte area or hepatic lipid

contents after leptin/IOP treatment.
The present studies confirm the ability of leptin to

reduce hepatic lipid content and the body's ability to
store lipid in the proper tissues (adipose). However, there

is some kind of dysregulation in this process in the face
of reduced thyroid hormone concentration. The interaction

between leptin and T3 is poorly understood and needs further
investigation .

IOP and leptin/IOP treated mice decreased mean daily
food consumption in the present study compared to vehicle

treated mice, whereas Underhill (2000) found a decrease in
only the leptin and leptin/IOP treated mice. The IOP

treated mice in the present study became sick in the first
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couple of days of treatment. Therefore, the differences
seen within this group between the present study and

Underhill (2000) may be due to the mice not eating the
first couple of days. In Underhill's study, mice receiving
IOP did get sick, but there is no record of them not

eating. Furthermore, in Underhill's study, food consumption
was not reported mass specifically.
Relative changes in body mass were different between

the two studies. While both the vehicle and leptin/IOP

groups in both studies showed weight gain or weight loss,
respectively, the leptin treated mice in the present study
did not change in body mass while the same treatment group

in Underhill's study did. Moreover, IOP treated mice in the

present study lost weight while in Underhill's study those

mice increased in body mass. In the present study, the
sickness in the IOP treated mice may be the cause of the

decreased food consumption as well as the decreased body

mass. I predicted that the IOP treated mice should eat
similar amounts of food relative to vehicle treated mice
and should gain a similar amount of weight because low

thyroid hormone concentration results in decreased

lipolysis and p-oxidation.
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Oxygen consumption rates in Underhill's study were

approximately 4 ml O2-min_1 for vehicle, leptin, and
leptin/IOP treated mice. He did not report mass-specific

V02. In the present study, all of the mice consumed about

3.00 ± 0.16 ml 02-min“1 (0.03 ± 0.0016 ml 02-min_1 -g-1).
Underhill's study showed all groups with an RQ of 0.7,
indicating lipid metabolism. The RQ in the present study
showed the leptin/IOP group had an RQ of 0.78, showing a

tendency to utilize lipids in metabolism, but the other
three groups had values of 0.86 ± 0.012, indicating both

carbohydrate and lipid metabolism.
Underhill's treatments were done for nine days,
whereas in the present study they were done for only seven
days. This may account for some of the differences seen

between these. However, Underhill also did not take body
mass into account in his analyses, and mice became ill in
the present study. Body weight can affect the analysis

because the size of an animal will alter some of the

parameters assessed. Taking all of these complicating

factors into account, it is clear that metabolic parameters
in the C57BL/6J ob/ob mice need to be reanalyzed for a
better understanding of what leptin and reduced thyroid
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hormone concentrations will do to lipid metabolism in the

absence of starvation.

Conclusion and Future Study
Since the IOP treatment in a previous study (Reno and
Fehn 2007) resulted in massive hepatic steatosis, we

wondered if IOP treatment combined with leptin would have
the same effect on liver lipid content as leptin treatment

alone. This hypothesis was not supported. The massive
hepatic steatosis observed in leptin/IOP treated mice, and
lack of steatosis in leptin treated mice, may indicate that
leptin and thyroid hormone work together at one of the
lipid export pathways. In addition, the hepatic LD content

in leptin/IOP treated mice suggests that there is
obstruction in lipid breakdown as well as export.
Therefore, there may be multiple pathways at which these
two hormones work in concert. The hypothesis that leptin

administered in combination with IOP will correct the lipid

trafficking dysregulation (including reduce hepatic
steatosis) observed in a lowered thyroid hormone

environment was not supported. Due to the starvation that
occurred in two of the groups, this study has not
conclusively established a relationship between leptin and

thyroid hormone in lipid trafficking in obese mice.
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However, the observations and comparisons made herein

further support the possibility of such an interaction.
Further studies to isolate proteins involved in the process
of hepatic lipid breakdown and export may reveal what such
an interaction might be. Experiments that look at the role
of apoB and very low density lipoproteins (VLDLs) in

packing lipids for export may help us understand if this
postulated interaction is at the site of hepatic lipid

export. In addition, markers that follow 0-oxidation may
elucidate if decreased lipid metabolism in the hepatocytes

is the cause of the observed steatosis. A better

understanding of these processes may provide possible
routes for therapy in obese patients.
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LIST OF ABBREVIATIONS
6OHDA: 6-hydroxydopanine
a-MSH: melanocortin stimulating hormone

AgRP: agouti-related peptide
ATGL: adipose triglyceride lipase
CNS: central nervous system

DAG: diacylglycerol
DIT: 3, 5-diiodotyrosine
ER: endoplasmic reticulum

HSL: hormone sensitive lipase

IOP: iopanoic acid
LD: lipid droplet

MIT: 3-monoiodotyrosine

NPY: neuropeptide Y
ob/ob: leptin deficient obese mice

POMC: proopiomelanocortin
RQ: respiratory quotient

SE: sterol ester

SNS: sympathetic nervous system
T3: 3,5,3'-triido-L-thyronine
T4: 3,5,3' , 5' -tetraiodo-L-thyronine

TEM: transmission electron microscopy

Tg: thyroglobulin
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TG: triacylglycerol
TGH: triacylglycerol hydrolase

TR: thyroid receptor
TRE: thyroid response element

TSH: thyroid stimulating hormone

V02= oxygen consumption rate
WE: wax ester
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RECIPE OF SOLUTIONS

The vehicle solution was prepared with 20 mN Tris/HCl,

pH 8.0. Five mice received a daily dose of 3 pl/g Mb
vehicle. Leptin (R and D3 systems, #498-OB) was dissolved

in 20 mM Tris/HCl, pH 8.0, as directed by the manufacturer.

Five mice received a daily dose of 3 pg/g Mb of leptin (3
pl/g Mb of 1 pg/pl). Iopanoic acid (Methimazole, Western
Medical Supply) was prepared under a fume hood by pondering

tablets with a mortar and pestle while the tablets were

still in foil. The powder was transferred to a vial, mixed

with 0.1 M NaOH, and sonicated to dissolve, giving a
concentration of 15 pg/pl. This solution was combined with
0.1 M HC1 and resonicated. The pH was brought to about 7.8

with 0.1 M HC1. The solution was sonicated again and
diluted with distilled water. Five mice received a daily
dose of 50 pg/g Mb IOP (3.33 pl/g Mb of 15 pg/pl). All of
the above doses were chosen based on success with previous

experimentation with the same dosages in ob/ob mice (Fehn

et al. 1999; Reno and Fehn 2007).
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The leptin and saline solutions were made, aliquoted,
and stored at -20 °C until use. The IOP was made fresh

every morning just prior to use.
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TEM EMBEDDING
The liver pieces were placed in a 2.5%

glutaraldehyde/Tyrode's Cacodylic acid solution for primary
fixation overnight. The next day, the tissues were washed
twice with cacodylic acid buffer (ph 7.4), incubated for
one hour and overnight, respectively. On day 3, the tissues

were incubated with fresh cacodylic acid buffer for 30
minutes. They then were allowed to post-fix with 2% osmium
tetroxide (OSO4) for about two hours. The tissues were

incubated with cacodylic acid buffer for one hour, followed
by a dehydration series starting at 50% ethanol and going
through to 100% dry ethanol. Each dehydration step required

45 min to 2 hours, with the higher concentrated alcohols
requiring the longer incubation times. The 100% dry ethanol

was replaced with 100% propylene oxide for 2 hours. This

solution was then replaced with a 1:2 epon:propylene oxide

mixture and allowed to incubate overnight on a rotator. On
day 4, the 1:2 epon:propylene oxide solution was replaced

with 1:1 epon:polypropylene oxide and allowed to incubate
for 2 hours while rotating. This solution was replaced with

100% epon and allowed to penetrate into the tissues
overnight while on a rotator. All the above mentioned steps

were done at room temperature. On day 5, the tissues and
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epon were placed into embedding capsules and allowed to
polymerize for approximately 18 hours at 60° C.
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